Az emlőrák szisztémás kezelése szakmai irányelvek /

Since the III. Breast Cancer Consensus Conference, a number of new evidence based on clinical trial results have been published which justified updating the 2016 recommendation. In addition to classical prognostic factors, some multigenic tests, which we have incorporated into the recommendation, wi...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Horváth Zsolt
Boér Katalin
Dank Magdolna
Kahán Zsuzsanna
Kocsis Judit
Kövér Erika
Pikó Béla
Máhr Károly
Rubovszky Gábor
Dokumentumtípus: Cikk
Megjelent: 2020
Sorozat:MAGYAR ONKOLÓGIA 64 No. 4
mtmt:31782991
Online Access:http://publicatio.bibl.u-szeged.hu/20382
Leíró adatok
Tartalmi kivonat:Since the III. Breast Cancer Consensus Conference, a number of new evidence based on clinical trial results have been published which justified updating the 2016 recommendation. In addition to classical prognostic factors, some multigenic tests, which we have incorporated into the recommendation, will play an important role in therapeutic decision-making. The professional guide primarily reflects the resolutions and recommendations of the current ESMO, NCCN, ABC4, as well as the St. Gallen Consensus Conference. From a didactic point of view, the text follows first the line of early and then locally advanced breast cancer, locoregionally recurrent and metastatic breast cancer. Within these, we discuss each group according to therapeutic options.
Terjedelem/Fizikai jellemzők:348-368
ISSN:0025-0244